Cancer-associated thrombosis – treatment and prevention with direct oral factor Xa inhibitors | Zendy

Kristína Grilusová | Zendy; Tomáš Bolek | Zendy; Ingrid Škorňová | Zendy; Ján Staško | Zendy; Matej Samoš | Zendy; Marián Mokáň | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cancer-associated thrombosis – treatment and prevention with direct oral factor Xa inhibitors

Author(s) -

Kristína Grilusová,

Tomáš Bolek,

Ingrid Škorňová,

Ján Staško,

Matej Samoš,

Marián Mokáň

Publication year - 2021

Publication title -

klinicka onkologie

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.204

H-Index - 13

eISSN - 1802-5307

pISSN - 0862-495X

DOI - 10.48095/ccko2021283

Subject(s) - medicine , edoxaban , apixaban , rivaroxaban , antithrombotic , intensive care medicine , venous thromboembolism , cancer , thrombosis , low molecular weight heparin , venous thrombosis , warfarin , atrial fibrillation

Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in patients with cancer. Moreover, management of VTE is frequently connected with complications, namely risk of recurrent VTE and bleeding. Low molecular weight heparins (LMWH) therapy administrated for 3-6 months is currently considered a standard for the treatment of cancer-associated VTE (CA-VTE). Direct oral factor Xa inhibitors (FXaI) apixaban, edoxaban and rivaroxaban have emerged as a new possibility for long-term antithrombotic therapy for VTE. These agents expose several advantages in individuals with cancer, and might overcome several disadvantages connected with LMWH therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research